Bylicki, Olivier

Chinese Academy of Medical Sciences & Peking Union Medical College · Peking University · McGill University Health Centre · Samsung Medical Center · Hôpital d'Instruction des Armées Sainte-Anne · Centre Hospitalier de l’Université de Montréal · National Cancer Center Hospital East · Kanagawa Cancer Center · Stanford Cancer Institute · Université de Montréal · Sungkyunkwan University · Stanford University

3 papers on CoChatORCID 0000-0001-8683-0969

Most cited papers

Verified
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine
Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 1,180
Verified
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Scherpereel, A., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., et al. (2019) · The Lancet Oncology
Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies
Cited by 454
Verified
ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date
Gendarme, S., Bylicki, O., Chouaid, C., & Guisier, F. (2022) · Current Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 121

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.